Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • December 19, 2018 9:29 AM | Anonymous

    December 19, 2018, MedPage Today  

    Women up to age 40 who have residual tumor in either the breast or lymph nodes following neoadjuvant chemotherapy had higher rates of recurrence compared with women with no residual invasive tumor, according to a retrospective study. 

    Read more. 

  • December 19, 2018 9:25 AM | Anonymous

    December 19, 2018, MedPage Today 

    The risk of pelvic floor disorders for women years after childbirth varied depending on mode of delivery, researchers found.Women with cesarean delivery had a lower hazard of stress urinary incontinence, overactive bladder, and pelvic organ prolapses compared with women with spontaneous vaginal deliveries, reported Joan L. Blomquist, MD, of Greater Baltimore Medical Center in Maryland, and colleagues.

    Read more.
  • December 18, 2018 11:24 AM | Anonymous

    December 18, 2018, HealthDay News  

    For treatment of human papillomavirus (HPV)-positive low-risk oropharyngeal cancer, cetuximab shows no benefit compared with the standard cisplatin regimen in terms of reduced toxicity and results in worse tumor control, according to a study recently published in The Lancet. 

    Read more. 

  • December 18, 2018 11:22 AM | Anonymous

    December 18, 2018, Medscape 

    Nearly half of patients with breast cancer who, on multigene panel testing, are found to have a pathogenic or likely pathogenic variant for breast cancer do not meet current National Comprehensive Cancer Network (NCCN) guidelines for genetic testing, new research shows.  

    Read more.

  • December 12, 2018 3:05 PM | Anonymous

    December 12, 2018, MedPage Today 

    The frequency of cardiotoxicity declined significantly with prophylactic antihypertensive medication for patients with early HER2-positive breast cancer treated with anthracycline-containing chemotherapy, but not trastuzumab (Herceptin), a randomized trial showed. 

    Read more.

  • December 12, 2018 3:03 PM | Anonymous

    December 12, 2018, MedPage Today  

    Extending adjuvant endocrine therapy with an aromatase inhibitor to 10 years led to significant improvement in disease-free survival (DFS) and distant (DDFS) in postmenopausal women with hormone receptor-positive (HR-positive) breast cancer, Japanese investigators reported. 

    Read more.


  • December 12, 2018 2:55 PM | Anonymous

    December 12, 2018, Medgadget  

    Ob/Gyn Hologic is releasing in the U.S. its new Omni three-in-one hysteroscope, a device that gives physicians an option of three different sheaths on the same system. Using the Omni, one is not required to switch between diagnostic and operatives scopes, as it can serve different functions thanks to the three available sheaths. The product won U.S. Food and Drug Administration clearance earlier this month. 

    Read more.

  • December 11, 2018 2:03 PM | Anonymous

    December 11, 2018, HealthDay News via Monthly Prescribing Reference  

    From 2012 to 2016, there was a 61% increase in syphilis cases among pregnant women, with no traditional behavioral risk factors reported among half of these women, according to a study published online in Obstetrics & Gynecology. Researchers analyzed US national case report data from 2012 to 2016 to calculate trends among pregnant women with syphilis. They also examined the number of pregnant women in this population reporting high-risk behaviors. 

    Read more.

  • December 11, 2018 2:02 PM | Anonymous

    December 11, 2018, Health Central  

    Mayo Clinic researchers have found that the urinary incontinence medication oxybutynin (Oxytrol, Ditropan XL) can reduce the severity and frequency of hot flashes in menopausal women who aren't able to take hormone replacement therapy (HRT), including women who've had breast cancer. The researchers presented their findings at the 2018 San Antonio Breast Cancer Symposium.  

    Read more.

  • December 11, 2018 9:08 AM | Anonymous

    ARHP is supporting an important effort by the Planned Parenthood Federation of America (PPFA). Courtney Benedict, MSN, CNM, FNP of PPFA is conducting a survey of advanced practice clinicians (APCs), including nurse practitioners, nurse-midwives, licensed midwives and physician assistants, to assess their interest and engagement in working in the delivery of sexual and reproductive health (SRH) care. Specifically, this survey will:

    • Ask about your interest in and motivations for working in SRH
    • Identify needs of APCs interested in SRH work and
    • Identify needs of APCs already engaged in SRH

    This survey is part of a larger organizational project seeking to define motivators and barriers to APC’s participation in the SRH workforce. The findings from this study will be analyzed and published as potential strategies for the recruitment and retention of APCs in the SRH workforce.

    Your participation in this survey is voluntary and you can stop participation at any time. Your answers are anonymous and the data will be kept confidential and only shared publicly in aggregated forms which would prevent identification of individual responses.

    This survey should take approximately 15-20 minutes to complete and for your participation, you will have the option to be entered into a raffle to win one of several $250 gift cards. Your valuable time and insight is appreciated.

    If you have any questions, please contact Courtney Benedict at Courtney.benedict@ppfa.org or at 415-828-1487.

    Click Here to Take the Survey


Powered by Wild Apricot Membership Software